Investing.com - Fulgent Genetics (NASDAQ:FLGT) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Fulgent Genetics announced earnings per share of $0.06 on revenue of $105.66M. Analysts polled by Investing.com anticipated EPS of $0.17 on revenue of $103.7M.
Fulgent Genetics shares are up 6% from the beginning of the year, still down 67.58% from its 52 week high of $109.55 set on December 20, 2021.
Fulgent Genetics shares lost 9.83% in after-hours trade following the report.
Fulgent Genetics follows other major Healthcare sector earnings this month
Fulgent Genetics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar